Compare AbCellera Biologics Inc (ABCL) vs Aspen Aerogels Inc (ASPN) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

ASPN trades at $5.47, down 1.97% today, with a bearish technical signal despite bullish moving averages. The company reported a Q1 2026 net loss of $0.28 per share, missing estimates, but revenue beat expectations. Recent news includes a 2025 Supplier of the Year award from General Motors and the staged restart of its East Providence facility after an incident. Cash flow improved in 2026 projections, with net cash flow narrowing to -$17 million from -$63 million in 2025.

Outlook remains challenging with persistent losses and negative margins, but analyst sentiment is strongly bullish (83% buy ratings). Key risks include execution on facility restarts, EV demand volatility, and cash burn. The stock's investment case hinges on operational turnaround and revenue growth acceleration amid competitive pressures.